{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-019995","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2026-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.756435+00:00","generated_at":"2026-05-15T09:29:38.403252+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Rhythm Pharma wins FDA approval for IMCIVREE in acquired hypothalamic obesity; Phase 3 shows -18.4% BMI reduction","bullets":["FDA approved IMCIVREE (setmelanotide) for acquired HO in adults and children 4+; first approved therapy for this indication.","Phase 3 TRANSCEND: setmelanotide (-15.8% BMI) vs placebo (+2.6%) at 52 weeks; placebo-adjusted -18.4% (p<0.0001).","Most common AEs (>20%): skin hyperpigmentation, nausea, vomiting, headache.","Rhythm estimates ~10,000 U.S. patients with acquired HO; drug available immediately.","IMCIVREE already approved for BBS and monogenic obesity due to POMC/PCSK1/LEPR deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-019995","json":"https://secwatch.observer/filing/0001628280-26-019995.json","markdown":"https://secwatch.observer/filing/0001628280-26-019995.md","text":"https://secwatch.observer/filing/0001628280-26-019995.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/0001628280-26-019995-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:29:38.403252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}